Overview

A Study of IBI302 in Patients With nAMD

Status:
Active, not recruiting

Trial end date:
2023-05-31

Target enrollment:

Participant gender:

Summary

The study is designed for multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IBI302 in subjects with neovascular age-related macular degeneration.

Phase:

Phase 2

Details

Lead Sponsor:

Innovent Biologics (Suzhou) Co. Ltd.

Treatments:

Aflibercept